Coronavirus: how much protection can we expect from a future vaccine?
Oxford jab trials nearing completion - but experts dismiss hopes of ‘pandemic silver bullet’
With countries worldwide heading back into lockdown, speculation is growing about when a potential vaccine may become available to help alleviate the need for harsh Covid-19 restrictions.
UK Vaccine Taskforce chair Kate Bingham told MPs this week that while the Oxford University vaccine may be ready within weeks, production delays mean the first batch may total no more than four million doses. And concerns over how long coronavirus antibodies last have raised questions about whether multiple jabs may be needed to maintain immunity.
So how much protection can we expect from the first Covid vaccines?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
When will a vaccine be ready?
The director of the Oxford University vaccine trial has said there is a “small chance” of the jab being ready before Christmas.
Professor Andrew Pollard told MPs on the Commons Science and Technology Committee on Wednesday that he was “optimistic” the trial could present late-stage results before the end of the year - a development that “by historical standards, is phenomenal”, says the BBC’s health and science correspondent James Gallagher.
“It would normally take years, if not decades, to develop a vaccine,” Gallagher adds. “Just to get to this point has been a remarkable and unprecedented feat, and data will arrive soon which will define our lives for years.”
However, most experts have suggested that early to mid 2021 is a more realistic rollout date.
Hundreds of potential vaccines are being tested in countries across the globe, with 154 candidates currently in pre-clinical trials, 21 in small-scale human safety trials, 12 in more expanded safety trials, and 11 in wider testing and effectivness assessments.
How well will it work?
Dr Anthony Fauci, the chief of the US National Institute of Health and Infectious Disease, has warned for months that a vaccine may not be a silver bullet. Addressing a webinar hosted by Brown University in August, he said: “We don't know yet what the efficacy might be. We don't know if it will be 50% or 60%.”
Other experts have also called for caution. In a paper published in The Lancet in September, Sri Lankan virologist Malik Peiris and Hong Kong epidemiologist Gabriel M. Leung write that “we cannot assume Covid-19 vaccines, even if shown to be effective in reducing severity of disease, will reduce virus transmission to a comparable degree.
“The notion that Covid-19-vaccine-induced population immunity will allow a return to pre-Covid-19 ‘normalcy’ might be based on illusory assumptions.”
The US Food and Drug Administration has said that “once a vaccine is shown to be safe and at least 50% effective, it could be approved for use in the US”, reports NPR.
But in order to get 40% of a population immune through vaccination with this level of efficacy, “you’re going to have to vaccinate 80% of the population”, Carlos del Rio, an infectious disease expert at Emory University, told the Washington D.C.-based news site. “So it’s not going to happen right away.”
Study results published by Imperial College London in October throw up a further problem. The research revealed that antibodies against the coronavirus declined rapidly in the UK population over the summer months.
The findings suggests that the protection provided by vaccines may not last, raising questions over whether multiple jabs may be needed to ensure immunity.
Read more: who would be first to get vaccinated in the UK?
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
5 fact-checked cartoons about the VP debate
Cartoons Artists take on civil disagreements, admissions, and more
By The Week US Published
-
The Japanese villages where time stood still
The Week Recommends Up to 200 villagers cooperate to thatch a roof in a single day, preserving this beautiful tradition
By The Week UK Published
-
Crossword: October 6, 2024
The Week's daily crossword
By The Week Staff Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
Long Covid and chronic pain: is it all in the mind?
The Explainer 'Retraining the brain' could offer a solution for some long Covid sufferers
By The Week UK Published